Johnson & Johnson's Tremfya shows durable remission in Crohn's at two years
PositiveFinancial Markets

Johnson & Johnson's Tremfya has demonstrated impressive results in maintaining remission for Crohn's disease patients over a two-year period. This is significant as it offers hope for those struggling with this chronic condition, potentially improving their quality of life and reducing the need for more invasive treatments.
— Curated by the World Pulse Now AI Editorial System




